Medartis Holding AG (MED) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medartis Holding AG (MED) has a cash flow conversion efficiency ratio of 0.026x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF6.84 Million ≈ $8.65 Million USD) by net assets (CHF261.20 Million ≈ $330.23 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medartis Holding AG - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Medartis Holding AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Medartis Holding AG debt and liabilities for a breakdown of total debt and financial obligations.
Medartis Holding AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medartis Holding AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ami Organics Limited
NSE:AMIORG
|
0.006x |
|
Ramsay Generale De Sante
PA:GDS
|
0.060x |
|
Winall Hi tech Seed
SHE:300087
|
0.015x |
|
Luye Pharma Group Ltd
F:LUP
|
0.021x |
|
El Puerto de Liverpool S.A.B. de C.V
MX:LIVEPOLC-1
|
0.117x |
|
China Railway Tielong Container Logistics Co Ltd
SHG:600125
|
0.023x |
|
CAP S.A
SN:CAP
|
0.038x |
|
CompuGroup Medical SE & Co. KGaA
XETRA:COP
|
0.144x |
Annual Cash Flow Conversion Efficiency for Medartis Holding AG (2015–2024)
The table below shows the annual cash flow conversion efficiency of Medartis Holding AG from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Medartis Holding AG.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CHF269.65 Million ≈ $340.91 Million |
CHF32.07 Million ≈ $40.55 Million |
0.119x | +51.78% |
| 2023-12-31 | CHF254.96 Million ≈ $322.34 Million |
CHF19.98 Million ≈ $25.26 Million |
0.078x | +574.45% |
| 2022-12-31 | CHF237.78 Million ≈ $300.62 Million |
CHF-3.93 Million ≈ $-4.97 Million |
-0.017x | -117.66% |
| 2021-12-31 | CHF224.00 Million ≈ $283.19 Million |
CHF20.95 Million ≈ $26.49 Million |
0.094x | +58.02% |
| 2020-12-31 | CHF213.04 Million ≈ $269.33 Million |
CHF12.61 Million ≈ $15.94 Million |
0.059x | +57.27% |
| 2019-12-31 | CHF215.57 Million ≈ $272.54 Million |
CHF8.11 Million ≈ $10.26 Million |
0.038x | +27.36% |
| 2018-12-31 | CHF218.23 Million ≈ $275.91 Million |
CHF6.45 Million ≈ $8.15 Million |
0.030x | -95.43% |
| 2017-12-31 | CHF17.04 Million ≈ $21.54 Million |
CHF11.01 Million ≈ $13.92 Million |
0.646x | -7.16% |
| 2016-12-31 | CHF17.10 Million ≈ $21.62 Million |
CHF11.91 Million ≈ $15.06 Million |
0.696x | +375.23% |
| 2015-12-31 | CHF-46.95 Million ≈ $-59.36 Million |
CHF11.88 Million ≈ $15.02 Million |
-0.253x | -- |
About Medartis Holding AG
Medartis Holding AG, a medical device company, engages in the development, manufacturing, and sales of implant solutions worldwide. The company's medical devices are used for the treatment of surgical fixation of bone fractures for upper and lower extremities, as well as for the cranio-maxillofacial surgery. It provides osteosynthesis products for the hand, wrist, forearm, elbow, shoulder, and fo… Read more